- Johnson & Johnson's data supporting booster shots looks promising.
- That vaccine's lower initial efficacy compared to the other FDA-approved COVID-19 jabs could increase the likelihood of it receiving authorization for booster shots.
Pfizer (NYSE:PFE) has already won authorization to inoculate people with boosters of its COVID-19 vaccine, albeit thus far, only those in certain higher-risk groups. Moderna (NASDAQ:MRNA) and Johnson & Johnson (NYSE:JNJ) will now have their first chance to join it with a Food and Drug Administration advisory committee reviewing data for their boosters. In this Motley Fool Live video recorded on Sept. 22, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Johnson & Johnson's booster shot opportunity could be greater than Pfizer's or Moderna's.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.